Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경효 | * |
dc.date.accessioned | 2019-07-29T16:31:07Z | - |
dc.date.available | 2019-07-29T16:31:07Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0022-1899 | * |
dc.identifier.issn | 1537-6613 | * |
dc.identifier.other | OAK-22590 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/250291 | - |
dc.description.abstract | Background. A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002). Methods. Participants (N = 2519) were vaccinated at day 1 and months 2 and 6. Gynecological samples (Study 001 only) and serum were collected for HPV DNA and antibody assessments, respectively. Injection-site and systemic adverse events (AEs) were monitored. Data were analyzed by country and vaccination group. Results. 9vHPV vaccine prevented HPV-31/33/45/52/58-related persistent infection with 90.4%-100% efficacy across included countries. At month 7, >= 97.9% of participants seroconverted for each HPV type. Injection-site AEs occurred in 77.7%-83.1% and 81.9%-87.5% of qHPV and 9vHPV vaccine recipients in Study 001, respectively, and 62.4%-85.7% of girls/boys in Study 002; most were mild to moderate. Conclusions. The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Asian participants. Data support 9vHPV vaccination programs in Asia. | * |
dc.language | English | * |
dc.publisher | OXFORD UNIV PRESS INC | * |
dc.subject | 9vHPV | * |
dc.subject | Asia | * |
dc.subject | cervical cancer | * |
dc.subject | human papillomavirus | * |
dc.subject | vaccine | * |
dc.title | Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 218 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 95 | * |
dc.relation.lastpage | 108 | * |
dc.relation.journaltitle | JOURNAL OF INFECTIOUS DISEASES | * |
dc.identifier.doi | 10.1093/infdis/jiy133 | * |
dc.identifier.wosid | WOS:000434930900012 | * |
dc.identifier.scopusid | 2-s2.0-85048443828 | * |
dc.author.google | Garland, S. M. | * |
dc.author.google | Pitisuttithum, P. | * |
dc.author.google | Ngan, H. Y. S. | * |
dc.author.google | Cho, C-H | * |
dc.author.google | Lee, C-Y | * |
dc.author.google | Chen, C-A | * |
dc.author.google | Yang, Y. C. | * |
dc.author.google | Chu, T-Y | * |
dc.author.google | Twu, N-F | * |
dc.author.google | Samakoses, R. | * |
dc.author.google | Takeuchi, Y. | * |
dc.author.google | Cheung, T. H. | * |
dc.author.google | Kim, S. C. | * |
dc.author.google | Huang, L-M | * |
dc.author.google | Kim, B-G | * |
dc.author.google | Kim, Y-T | * |
dc.author.google | Kim, K-H | * |
dc.author.google | Song, Y-S | * |
dc.author.google | Lalwani, S. | * |
dc.author.google | Kang, J-H | * |
dc.author.google | Sakamoto, M. | * |
dc.author.google | Ryu, H-S | * |
dc.author.google | Bhatla, N. | * |
dc.author.google | Yoshikawa, H. | * |
dc.author.google | Ellison, M. C. | * |
dc.author.google | Han, S. R. | * |
dc.author.google | Moeller, E. | * |
dc.author.google | Murata, S. | * |
dc.author.google | Ritter, M. | * |
dc.author.google | Sawata, M. | * |
dc.author.google | Shields, C. | * |
dc.author.google | Walia, A. | * |
dc.author.google | Perez, G. | * |
dc.author.google | Luxembourg, A. | * |
dc.contributor.scopusid | 김경효(35448653000) | * |
dc.date.modifydate | 20240301081003 | * |